In the following video, Motley Fool health-care analyst David Williamson takes a look at Mylan (MYL), and its recent agreement to acquire generic injectable products maker Agila Specialties from Strides Arcolab, for $1.6 billion in cash. David tells investors how this deal doubles Mylan's exposure to the high-margin biosimilars market, just as the Affordable Care Act is creating provisions for a pathway to bring biosimilars through an approval process and out to market.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.